Fundraising FoxPontifax Venture Capital — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)
Board seatRan Nussbaum· per SEC Form D
Co-investorsPivotal Life SciencesTarnagulla VenturesVida VenturesTCG Crossover
Graviton develops immunomodulatory therapies for patients with fibrotic, autoimmune, and central nervous system diseases.
AI & Machine LearningBiotechDeep TechHealthtechNew York, US
Samuel Waksal(Founder & CEO)Steven Gordon(Executive Officer, Director)
BoardPhilip Barach(Director)Richard Giroux(Director)
Board seatRan Nussbaum· per SEC Form D
Co-investorsInnova Capital Partners, LLC
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.
BiotechHealthtechMedical Devices
Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in
Co-investorsaMoonRA CapitalBpifranceAndera PartnersAngelini VenturesKurma Partners+1 more
Graviton offers an AI model trained on blockchain technology, including Solidity, to help developers build Web3 decentralized applications (dApps) from a prompt.
AI & Machine LearningCrypto & Web3Developer Tools
Co-investorsBlueYard Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.